ATE345788T1 - Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber - Google Patents

Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber

Info

Publication number
ATE345788T1
ATE345788T1 AT02718181T AT02718181T ATE345788T1 AT E345788 T1 ATE345788 T1 AT E345788T1 AT 02718181 T AT02718181 T AT 02718181T AT 02718181 T AT02718181 T AT 02718181T AT E345788 T1 ATE345788 T1 AT E345788T1
Authority
AT
Austria
Prior art keywords
virally induced
treatment
fever
inhibitors
mediated
Prior art date
Application number
AT02718181T
Other languages
English (en)
Inventor
Dorian Bevec
Ute Stroher
Hans-Dieter Klenk
Christian Wallasch
Original Assignee
Dorian Bevec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dorian Bevec filed Critical Dorian Bevec
Application granted granted Critical
Publication of ATE345788T1 publication Critical patent/ATE345788T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT02718181T 2001-03-06 2002-03-06 Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber ATE345788T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01105552 2001-03-06
US27464701P 2001-03-12 2001-03-12

Publications (1)

Publication Number Publication Date
ATE345788T1 true ATE345788T1 (de) 2006-12-15

Family

ID=32523996

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02718181T ATE345788T1 (de) 2001-03-06 2002-03-06 Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber

Country Status (5)

Country Link
US (1) US20040122058A1 (de)
EP (1) EP1420778B1 (de)
AT (1) ATE345788T1 (de)
AU (1) AU2002249261A1 (de)
WO (1) WO2002069960A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US7132398B2 (en) 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
AU2004283148A1 (en) 2003-10-21 2005-05-06 Warner-Lambert Company Llc Polymorphic form of N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
BRPI0506148A (pt) * 2004-06-25 2006-10-24 Fibrex Medical Res & Dev Gmbh preparação farmacêutica para o tratamento de choque
WO2006091610A2 (en) * 2005-02-23 2006-08-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity
DE102008010362A1 (de) * 2008-02-18 2009-08-20 Florian Prof. Dr. Lang Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen
JP6194003B2 (ja) 2012-10-09 2017-09-06 ザ プロクター アンド ギャンブル カンパニー 有益剤及びこれを含む組成物の特定又は評価方法
EP2906197A1 (de) 2012-10-09 2015-08-19 The Procter & Gamble Company Verfahren zur identifizierung synergistischer kosmetischer kombinationen
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111529532A (zh) * 2020-05-05 2020-08-14 华中科技大学同济医学院附属协和医院 曲美替尼在制备治疗肺部炎症性疾病药物及促进Tfh细胞分化药物中的应用
EP3912623A1 (de) * 2020-05-20 2021-11-24 Atriva Therapeutics GmbH Mek-inhibitoren zur behandlung von coronavirus-infektionen und/oder covid-19-cytokin-sturm

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
AU2203800A (en) * 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
CA2362380A1 (en) * 1999-03-19 2000-09-28 Bristol-Meyers Squibb Pharma Company Amino-thio-acrylonitriles as mek inhibitors
CA2362705A1 (en) * 1999-03-19 2000-09-28 Joseph B. Santella, Iii N-adamant-1-yl-n'-¬4-chlorobenzothiazol-2-yl| urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent

Also Published As

Publication number Publication date
AU2002249261A1 (en) 2002-09-19
WO2002069960A2 (en) 2002-09-12
EP1420778A2 (de) 2004-05-26
US20040122058A1 (en) 2004-06-24
EP1420778B1 (de) 2006-11-22
WO2002069960A3 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
ATE345788T1 (de) Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
ATE325612T1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
NO20045247L (no) Nukleosidderivater for behandling av hepatitt C-virusinfeksjon
ATE524195T1 (de) Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen
DE602005023587D1 (de) Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
DE122012000007I1 (de) Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung.
BR0209821A (pt) Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
NO20072461L (no) Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme
NO20075655L (no) Terapeutisk RNAI for respiratorisk virusinfeksjon
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
NO20083032L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av mani og bipolar forstyrrelse
ATE336996T1 (de) Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem
CY1124762T1 (el) Αναστολεις πρωτεïνης δεσμευσης creb (cbp)
ATE446514T1 (de) VERWENDUNG VON ßHYPOXIA INDUCIBLE FACTOR 2ALPHAß ZUR BEHANDLUNG VON ßNEONATAL RESPIRATORY DISTRESS SYNDROMEß
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
BR112022001025A2 (pt) Inibidores de calicreína plasmática
ATE551319T1 (de) Sgk1-inhibitoren zur prophylaxe und/oder therapie von viralen erkrankungen und/oder karzinomen
DE60329326D1 (de) Tace inhibitoren
DE69730214D1 (de) Zusammensetzung und verfahren zur behandlung von herpes simplex
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE328898T1 (de) Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung
WO2020242719A3 (en) Inhibitors of rna-binding proteins, compositions thereof, and therapeutic uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties